Similarly, this study found that the median PSA level was 34.1 ng/mL before neoadjuvant therapy, then decreased to 0.8 ng/mL after neoadjuvant therapy, and further dropped to 0.0 ng/mL at M12 in patients with high-risk prostate cancer who received Boennuokang® leuprorelin acetate microspheres-based treatment as neoadjuvant therapy. This evidence concerns the gene KLK3 and prostate cancer.